


PHARMACEUTICAL 2022

Monopar Therapeutics

Monopar Therapeutics Rank 268 of 475



RealRate

PHARMACEUTICAL 2022



Monopar Therapeutics Rank 268 of 475

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 210% points. The greatest weakness of Monopar Therapeutics is the variable Net Income, reducing the Economic Capital Ratio by 123% points.

The company's Economic Capital Ratio, given in the ranking table, is -146%, being 131% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	20,522
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	4.7
Other Expenses	0
Other Liabilities	1,581
Other Net Income	24
Property and Equipment	0
Research and Development	6,493
Revenues	0
Selling, General and Administrative Expense	2,634

Output Variable	Value in 1000 USD
Assets	20,522
Liabilities	1,581
Expenses	9,127
Stockholders Equity	18,941
Net Income	-9,103
Comprehensive Net Income	-9,101
Economic Capital Ratio	-146%